ReviewMolecular therapy. Methods & clinical development2016
Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.
Review in Molecular therapy. Methods & clinical development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Early to Late VSV-G Expression in AcMNPV BV Enhances Transduction in Mammalian Cells but Does Not Affect Virion Yield in Insect Cells.Vaccines · 2025Article
- Article
- Genome editing and kidney health.Clinical kidney journal · 2024Review
- P26 enhances baculovirus gene delivery by modulating the mammalian antiviral response.Applied microbiology and biotechnology · 2023Article
- Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine.Archives of Razi Institute · 2023Article
- Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.Virus research · 2023Article
- Article
- Current view on novel vaccine technologies to combat human infectious diseases.Applied microbiology and biotechnology · 2022Review
- Genetic engineering of baculovirus-insect cell system to improve protein production.Frontiers in bioengineering and biotechnology · 2022Review
- Current status and development prospects of aquatic vaccines.Frontiers in immunology · 2022Review
- Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies.Applied microbiology and biotechnology · 2021Review
- Production of Rabies VLPs in Insect Cells by Two Monocistronic Baculoviruses Approach.Molecular biotechnology · 2021Article
- Mixtures of Insect-Pathogenic Viruses in a Single Virion: towards the Development of Custom-Designed Insecticides.Applied and environmental microbiology · 2021Article
- Mucosal Administration of Recombinant Baculovirus DisplayingFrontiers in cellular and infection microbiology · 2021Article
- On Mr. Hyslop's prediction, content archives, and preprint servers.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Baculovirus-assisted Reovirus Infection in Monolayer and Spheroid Cultures of Glioma cells.Scientific reports · 2017Article
- Review
- Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles.Bioconjugate chemistry · 2016Article
- Towards routine manufacturing of gene therapy drugs.Molecular therapy. Methods & clinical development · 2016Article
- Targeted Inhibition of the miR-199a/214 Cluster by CRISPR Interference Augments the Tumor Tropism of Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells under Hypoxic Condition.Stem cells international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, baculoviruses have become workhorse research tools for transient transgene expression. Although they have not yet been used directly as a gene therapy vector in the clinical setting, numerous preclinical studies have suggested the highly promising potential of baculovirus as a delivery vector for a variety of therapeutic applications including vaccination, tissue engineering, and cancer treatment. As such, there is growing interest in using baculoviruses as human gene therapy vectors, which has led to advances in baculovirus bioprocessing methods. This review provides an overview of the current approaches for scaled-up amplification, concentration, purification, and formulation of AcMNPV baculoviruses, and highlights the key regulatory requirements that must be met before gene therapy clinical trials can be initiated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.